-
- Position
- ASSOCIATE PROFESSOR | Medicine, Nephrology
-
- Specialty
- Nephrology
-
- Language
- English
-
- Hospital Affiliations
- Mount Sinai Queens
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
In the News
Dr. Radbill discusses chronic kidney disease in The Daily News feature The Daily Check Up.
View the PDF.
Certifications
Nephrology
American Board of Internal Medicine
Clinical Focus
- Chronic Renal Failure
- Dialysis
- Glomerulonephritis
- Hematuria
- High Blood Pressure
- Kidney Biopsy
- Kidney Failure
- Kidney Stones
- Nephrotic Syndrome
- Renovascular Hypertension
Education
BA, University of Michigan
MD, Hahnemann University School of Medicine
MD, Hahnemann University
, Mount Sinai School of Medicine
, Mount Sinai School of Medicine
Internship, Internal Medicine
Mount Sinai Hospital
Residency, Nephrology
Mount Sinai Hospital
Fellowship, Nephrology
Mount Sinai Hospital
Language
English
Frequent Hemodialysis Network (FHN): Short Daily Dialysis Study
Previously published data suggests that short daily hemodialysis (2-2.5 hours a day, 6 days a week) may be superior to conventional hemodialysis (3-4 hours a day, 3 days a week) in terms of solute clearance and fluid management. Daily hemodialysis could result in improved dialysis adequacy, improved blood pressure control, decreased cardiac disease (specifically, left ventricular hypertrophy), and decreased mortality. We are working with RRI (Renal Research Institute) as part of a multi-center NIH funded clinical trial studying the potential benefits of short daily hemodialysis versus conventional hemodialysis.
The role of matrixmetalloproteinases (MMPs) in renal interstitial fibrosis
Renal interstitial fibrosis (RIF) is the end result of chronic kidney disease (CKD) and is predictive of long-term renal survival and its inhibition might delay progression towards end-stage renal disease (ESRD). Since type IV collagen-rich extracellular matrix is replaced by type-1 collagen after injury, the hypothesis is being tested that matrix metalloproteinase-2 (MMP-2), a type IV collagenase, may play a causative role in renal fibrosis. Mechanistic studies are underway using an MMP-2 -/- mouse to determine whether MMP-2 promotes renal tubular epithelial-mesenchymal transition (EMT), myofibroblast proliferation and fibrogenesis with and without unilateral ureteral obstruction (UUO), a murine model of RIF.
In addition, the role of MMP-2 in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) is under study comparing MMP-2 and fibrognesis marker gene and protein expression by human ADPKD epithelia versus normal renal tubular cell lines in vitro.
Vassalotti JA, Radbill BD, Klotman ME, Klotman PE. Hepatitis and HIV-related Renal Diseases. In: Brady HR, Wilcox CS, editors. Therapy in Nephrology and Hypertension. Companion to Brenner and Rector's The Kidney. 2nd Philadelphia, PA, W.B. Saunders Co; 2003. pp261-70.
Bansal MB, Kovalovich K, Gupta R, Li W, Agarwal A, Radbill B, Alvarez CE, Safadi R, Fiel MI, Friedbam SL, Taub RA. Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression. J Hepatol 2005 Apr; 42(4): 548-56.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Radbill did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.